Recently the use of bioactive α-glucosidase inhibitors for the treatment of diabetes have
been proven to be the most efficient remedy for controlling postprandial hyperglycemia and …

The metabolic syndrome, by definition, is not a disease but is a clustering of individual
metabolic risk factors including abdominal obesity, hyperglycemia, hypertriglyceridemia …

Diabetes is a common metabolic disorder marked by unusually high plasma glucose levels,
which can lead to serious consequences such as retinopathy, diabetic neuropathy and …

Lipids encompass a wide variety of molecules such as fatty acids, sterols, phospholipids,
and triglycerides. These molecules represent a highly efficient energy resource and can act …

Many of the comorbidities of obesity, including type 2 diabetes and cardiovascular diseases,
are related to the low‐grade chronic inflammation of white adipose tissue. Under white …

Chronic inflammation remains an essential complication in the pathogenesis and
aggravation of metabolic diseases. There is a growing interest in the use of medicinal plants …

Dietary odd-chain saturated fatty acids (OCFAs) are present in trace levels in dairy fat and
some fish and plants. Higher circulating concentrations of OCFAs, pentadecanoic acid (C15 …

Background. Sodium‐glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase‐4 (DPP‐4)
inhibitors are glucose‐lowering drugs whose anti‐inflammatory properties have recently …

It is recognized that a chronic low-grade inflammation and an activation of the immune
system are involved in the pathogenesis of obesity-related insulin resistance and type 2 …

Obesity has been described as a global epidemic and is a low-grade chronic inflammatory
disease that arises as a consequence of energy imbalance. Obesity increases the risk of …